In addition, the BMP-antagonist noggin appears to facilitate decreased bone formation in an animal model of prostate cancer bone metastasis (30) and in a number of osteolytic cell lines in vitro with prostate-derived cancer cell lines expressing higher levels of noggin than breast cancer derived cells [52]. Here, NOG is linked to prostate cancer.